Globeflex Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Globeflex Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-54	Closed	–	–	479
2016 Q3	$0	Sell	54 -291,887	-100%	-$1.17M	﹤0.01%	482
2016 Q2	$829K	Sell	291,941 -122,000	-29%	-$379K	0.23%	173
2016 Q1	$1.17M	Buy	413,941 +293,645	+244%	+$1.3M	0.31%	104
2015 Q4	$1.24M	Buy	+120,296	New	+$1.2M	0.33%	94

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Globeflex Capital's BCRX Position: Q4 2016 in Review

Globeflex Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2016, closing a stake of 54 shares.

Globeflex Capital first reported a position in BCRX in Q4 2015 and held it in 4 quarters. The position peaked at $1.24M in Q4 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

Globeflex Capital reported no remaining BioCryst Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Globeflex Capital sold 54 BioCryst Pharmaceuticals shares in Q4 2016.
Globeflex Capital first reported a position in BioCryst Pharmaceuticals in Q4 2015 and held it in 4 quarters.
Globeflex Capital's BioCryst Pharmaceuticals position peaked at $1.24M in Q4 2015.
112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on Globeflex Capital's 13F filing for Q4 2016, filed 13 Feb 2017.